Imalek Imatinib Tablets 100mg

  • Product Name : Imalek Imatinib Tablets 100mg
  • Category : Anti Cancer
  • Manufacturer Name : Sun Pharma
  • Trade Name : Imalek
  • Available Dosage : 100 MG
  • Packing : 10 Tablets
  • Pack Insert/Leaflet : 1 Pack (10 Tablets)
  • Ingredients : Imatinib Mesylate
  • Formulation : Tablet
  • Therapeutic use : Blood Cancer
  • Production Capacity : 100000

Description:-

Introduction to Imalek 100mg Tablet: 

Navigating the Landscape of Cancer Care Imalek 100mg Tablet stands as a stalwart companion in the battle against various forms of cancer. Primarily designated for blood cancers such as chronic myeloid leukemia and acute lymphocytic leukemia, as well as gastrointestinal stromal tumors, this medication embarks on a targeted mission to thwart the growth and dissemination of cancer cells.


Versatility in Application: Beyond Conventional Bounds

The scope of Imalek 100mg Tablet extends beyond the realms of blood cancers, encompassing the treatment of dermatofibrosarcoma protuberans, a skin tumor, and aggressive systemic mastocytosis, a specific bone marrow condition. Administered with food, the tablet's efficacy thrives when taken consistently at the same time each day, aligning with the symbiotic rhythm of optimal benefit and adherence.


The Art of Healing: Imalek 100mg Tablet in Action


For Blood Cancers, Gastrointestinal Stromal Tumors, Skin Cancer, and Bone Marrow Conditions:

Imalek 100mg Tablet orchestrates a targeted assault on the specific proteins instrumental in fueling the growth and dissemination of cancer cells. Its precision lies in disrupting these proteins, halting the relentless march of cancer. As a consequence, tumors shrink, their growth decelerates, and patients experience an amelioration in their well-being. Vigilance and adherence to prescribed regimens underscore the therapeutic dance, ensuring a harmonious balance between benefit and potential side effects.


Mechanism Unveiled: The Symphony of Action

Imalek 100mg Tablet operates as an anti-cancer juggernaut, taking aim at the bcr-abl tyrosine kinase protein enzyme. This enzyme, a catalyst for the abnormal proliferation of cancer cells, falls prey to the inhibitory prowess of Imalek. By curbing proliferation and inducing planned cell death (apoptosis) in bcr-abl positive cells, the medication emerges as a sentinel in arresting or slowing the insidious spread of cancer.